Detalles de la búsqueda
1.
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
Nat Immunol
; 21(11): 1346-1358, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32868929
2.
An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells.
Immunity
; 53(1): 187-203.e8, 2020 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32640259
3.
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Nature
; 603(7903): 942-948, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35322232
4.
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Nature
; 600(7890): 727-730, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34912120
5.
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Lancet Oncol
; 25(2): 212-224, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38134948
6.
Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential.
Cancer Sci
; 115(5): 1622-1633, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38429886
7.
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 401(10389): 1655-1668, 2023 05 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37068504
8.
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial.
Lancet
; 402(10418): 2197-2208, 2023 12 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37871604
9.
Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review.
Oncologist
; 29(5): e601-e615, 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38366864
10.
Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: a plain language summary of the DESTINY-Gastric01 study.
Future Oncol
; 20(2): 59-70, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37916503
11.
Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study.
Int J Clin Oncol
; 29(1): 27-35, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37964066
12.
First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
Int J Cancer
; 152(4): 749-760, 2023 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36121651
13.
Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma.
Cancer Sci
; 114(4): 1606-1615, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36478334
14.
Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.
Cancer Sci
; 114(2): 574-585, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35838190
15.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
N Engl J Med
; 382(25): 2419-2430, 2020 06 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-32469182
16.
HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability.
Gastroenterology
; 162(3): 799-812, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34687740
17.
Impact of Programmed Death-Ligand 1 Expression on Mismatch Repair Deficiency and Epstein-Barr Virus Status on Survival Outcomes in Patients with Stage II/III Gastric Cancer After Surgery.
Ann Surg Oncol
; 30(8): 5227-5236, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36934377
18.
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).
BMC Cancer
; 23(1): 180, 2023 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36814222
19.
Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience.
Gastric Cancer
; 26(6): 1030-1039, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37665515
20.
A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus.
Future Oncol
; 19(11): 739-752, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36919706